[Therapy of hepatitis B and hepatitis C coinfection in HIV patients].
Hepatitis coinfection represents a major risk for end stage liver disease in HIV-positive patients. For this reason, categorically every patient should be evaluated in respect to a specific treatment for hepatitis. The immunological benefit of HAART for hepatitis/HIV coinfected patients is not only a reduction of the risk for HIV disease, but also the reduction of the risk for liver associated diseases and outweighs the drawbacks of a potential hepatotoxicity of HAART. Thus, HAART should not be withheld from a patient because of hepatitis coinfection. When cirrhosis is present, semiannual prophylactic checkups are recommended to monitor the occurrence of hepatocellular carcinoma.
Vogel
M
M
Medizinische Universitätsklinik I, Bonn. martin.vogel@ukb.uni-bonn.de
Rockstroh
J K
JK
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000401:mortality; D023241:Antiretroviral Therapy, Highly Active; D015897:Comorbidity; D018450:Disease Progression; D004347:Drug Interactions; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins; D015996:Survival Rate; D019562:Viral Load
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a